HLTRF News and Press, HLS Therapeutics Inc From 12/16/20

HLS Therapeutics Announces Update on Health Canada Filings for MyCare and Trinomia Health Canada approves MyCare Psychiatry Lab Assays for use in diagnostic lab settings to measure blood levels in patients prescribed six of the most common antipsychotic drugs ...

HLS Therapeutics Reports Efficacy and Safety Results from Pilot Study Treating COVID-19 Infected Outpatients with Vascepa® (Icosapent Ethyl) Results presented in Late Breaker session at National Lipid Association Scientific Sessions 2020 Vascepa COVID-19 C...

HLS Therapeutics Establishes Automatic Share Purchase Plan Canada NewsWire TORONTO, Nov. 19, 2020 TORONTO , Nov. 19, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system a...

HLS Therapeutics Announces Health Canada Approval of PERSERIS® for the Treatment of Schizophrenia Canada NewsWire TORONTO, Nov. 17, 2020 first once-monthly risperidone long-acting injectable used in the treatment of schizophrenia once-monthly d...

VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Coronary Artery Bypass Grafting Procedures Canada NewsWire TORONTO, Nov. 16, 2020 Results from Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presen...

HLS Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference Canada NewsWire TORONTO, Nov. 12, 2020 TORONTO , Nov. 12, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focused on central...

HLS Therapeutics Announces Q3 2020 Financial Results and Normal Course Issuer Bid Canada NewsWire TORONTO, Nov. 5, 2020 Revenue of $13.1 million , Adjusted EBITDA of $4.5 million and cash from operations of $2.4 million Produced strong Vascepa...

HLS Therapeutics to Host Q3 2020 Financial Results Conference Call Canada NewsWire TORONTO, Oct. 27, 2020 TORONTO , Oct. 27, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q3 2020 financial results b...

HLS Therapeutics Highlights Latest Icosapent Ethyl Research Presented at the Canadian Cardiovascular Congress Canada NewsWire TORONTO, Oct. 22, 2020 In vitro data presented provides additional insight into potential mechanisms by which Vascepa reduces cardiovas...

HLS Therapeutics Acquires Portfolio of Four Royalty Interests Canada NewsWire TORONTO, Sept. 30, 2020 HLS anticipates the portfolio will generate sustained and diversified revenues and cash flows Portfolio forecasted to generate an IRR in excess of 20% pe...